Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase NA 11Phase 3 6Phase 1 4Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 18Prostatic Neoplasms 16Breast Neoplasms 11Recurrence 8Leukemia, Myeloid, Acute 8Neoplasm Metastasis 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Colorectal Neoplasms 6Ovarian Neoplasms 5Myelodysplastic Syndromes 5Multiple Myeloma 5Melanoma 5Leukemia 5Head and Neck Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Lymphoma, Non-Hodgkin 4Lung Neoplasms 4Fatigue 4Vomiting 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms, Castration-Resistant 3Pain 3Oropharyngeal Neoplasms 3Nausea 3Mesothelioma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Liposarcoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Taxes 1Ranitidine 1Paclitaxel 1Famotidine 1Diphenhydramine 1Dexamethasone 1Cimetidine 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Has results × Breast Carcinoma In Situ × Clear all
NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡